Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLoans - Loss AllowanceLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Current Deferred Revenue (2017 - 2025)

Historic Current Deferred Revenue for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $637293.3.

  • Innate Pharma's Current Deferred Revenue fell 7885.7% to $637293.3 in Q2 2025 from the same period last year, while for Jun 2025 it was $637293.3, marking a year-over-year decrease of 7885.7%. This contributed to the annual value of $666720.4 for FY2024, which is 8949.1% down from last year.
  • Innate Pharma's Current Deferred Revenue amounted to $637293.3 in Q2 2025, which was down 7885.7% from $658254.7 recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Current Deferred Revenue registered a high of $14.3 million during Q4 2021, and its lowest value of $637293.3 during Q2 2025.
  • For the 5-year period, Innate Pharma's Current Deferred Revenue averaged around $6.6 million, with its median value being $6.3 million (2023).
  • Examining YoY changes over the last 5 years, Innate Pharma's Current Deferred Revenue showed a top increase of 614.59% in 2021 and a maximum decrease of 9996.97% in 2021.
  • Quarter analysis of 5 years shows Innate Pharma's Current Deferred Revenue stood at $14.3 million in 2021, then crashed by 53.2% to $6.7 million in 2022, then decreased by 5.71% to $6.3 million in 2023, then plummeted by 89.57% to $658254.7 in 2024, then decreased by 3.18% to $637293.3 in 2025.
  • Its Current Deferred Revenue was $637293.3 in Q2 2025, compared to $658254.7 in Q4 2024 and $3.0 million in Q2 2024.